ritlecitinib (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

AdultPediatric

Alopecia Areata

Pending FDA approval for treatment of hair loss due to alopecia areata

Alopecia Areata

Pending FDA approval for treatment of hair loss due to alopecia areata in adults and adolescents aged ≥12 years

<12 years: Safety and efficacy not established

Next:

Pharmacology

Mechanism of Action

Dual inhibitor of the TEC family (ie, 5 nonreceptor protein tyrosine kinases [Tec, Btk, Itk/Emt/Tsk, Bmx, Txk/Rlk]) of tyrosine kinases and Janus kinase 3 (JAK3)

TEC kinase inhibitor; TEC kinases participate in signal transduction to promote immunological function; inhibition of TEC kinases reduce T cell and NK cell cytolyic function

JAKs pathways inhibitor; JAK consists of a group of intracellular tyrosine kinases that transmit signals from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function

Within the signaling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs), which modulate intracellular activity including gene expression; ritlecitinib modulates the signaling pathway at the point of JAKs, preventing STATs phosphorylation and activation

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.